4
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Thalidomide in the management of epidermolysis bullosa pruriginosa.

      The British Journal of Dermatology
      Adolescent, Epidermolysis Bullosa Dystrophica, drug therapy, genetics, Female, Humans, Immunosuppressive Agents, therapeutic use, Point Mutation, Prurigo, Thalidomide

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Epidermolysis bullosa (EB) pruriginosa is a distinctive clinical subtype of dystrophic EB. We report a patient with dominant dystrophic EB pruriginosa, who had an excellent response to systemic thalidomide treatment. The mechanism of action of thalidomide in the management of pruriginous disorders is not yet completely understood. Most recent studies point towards an immunomodulatory action of thalidomide that may suppress excessive production of tumour necrosis factor-alpha and may downregulate certain cell surface adhesion molecules involved in leucocyte migration.

          Related collections

          Author and article information

          Journal
          15949003
          10.1111/j.1365-2133.2005.06492.x

          Chemistry
          Adolescent,Epidermolysis Bullosa Dystrophica,drug therapy,genetics,Female,Humans,Immunosuppressive Agents,therapeutic use,Point Mutation,Prurigo,Thalidomide

          Comments

          Comment on this article